Edgewise Therapeutics(EWTX) - 2025 Q4 - Annual Results

Exhibit 99.1 – CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 – – Phase 1 healthy adult trial data of EDG-15400 and plans for heart failure studies expected in H1 2026 – – Pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy (Becker) expected in Q4 2026 – News Release Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascula ...